helping hematologists conquer blood diseases
About ASH | Patients | Media | Make a Gift | Corporate Supporters
Home > Education > Teach case > Romaguera >
  E-Mail This Page | Print This Page
MembershipMeetingsPublicationsEducation & CareersPolicy & PracticeASH Store


Find a Hematologist
Hematology Library

Blood
Image Bank
Education Program Book
ASH-SAP
Abstract Search
 
Teaching Cases

Lymphadenopathy – Jorge E. Romaguera, MD
M.D. Anderson Cancer Center, University of Texas, Houston, TX

Copyright of the American Society of Hematology, 2006. ISSN: 1931-6860.


I. History II. Physical Exam III. Laboratory Data IV. Differential Diagnosis
V. Pathophysiology VI. Prognosis/Clinical Course VII. Teaching Points VIII. Bibliography

VII. TEACHING POINTS

  1. Several disease processes can result in lymphadenopathy. Infectious etiologies should be excluded first (e.g., by Monospot and PPD tests to rule out EBV mononucleosis and tuberculosis respectively). A detailed history and physical examination is essential.
  2. Signs and symptoms of Non-Hodgkin’s Lymphoma (NHL) can be non-specific and are usually of little help in obtaining a diagnosis. Constitutional symptoms may include fever, night sweats, and weight loss.
  3. If no infection can be found, the diagnosis of lymphoma should be considered, and the diagnostic procedure of choice is excisional biopsy. Fine needle aspirations are less invasive, but not adequate to examine nodal architecture.
  4. The classification of Non-Hodgkin’s Lymphomas has been a challenge for many decades. Basically, lymphoma arises from an accumulation of mutations resulting in transformation of a lymphoid lineage cell. The malignant cells usually maintain many features of the specific stage of lymphoid development from which the clone arose. The most recent classification scheme (WHO or R.E.A.L system) utilizes multiple techniques, including morphology, immunostaining and molecular studies to obtain a specific diagnosis.
  5. Aggressive Non-Hodgkin’s Lymphoma should be treated upon diagnosis with multi-agent chemotherapy, often combined with the anti-CD20 antibody rituximab. Even patients with advanced stage disease can be cured with this approach.
  6. Low-grade NHL is incurable in most cases. Patients with low-grade NHL can be observed without therapy until they develop bulky or symptomatic lymph node or organ involvement.

View Bibliography

Have a question or comment about the ASH Teaching Cases? Please e-mail webmaster@hematology.org.

 

 

Contact Us   |   Terms of Use   |   Photo Credit   |   RSS

1900 M Street, NW, Suite 200    Washington, DC 20036    Phone: 202-776-0544    Fax: 202-776-0545    E-mail: ash@hematology.org

©2008 American Society of Hematology